388 related articles for article (PubMed ID: 34628065)
1. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
Mullol J; Bachert C; Amin N; Desrosiers M; Hellings PW; Han JK; Jankowski R; Vodicka J; Gevaert P; Daizadeh N; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1086-1095.e5. PubMed ID: 34628065
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
Chuang CC; Guillemin I; Bachert C; Lee SE; Hellings PW; Fokkens WJ; Duverger N; Fan C; Daizadeh N; Amin N; Mannent LP; Khan AH; Kamat S
Laryngoscope; 2022 Feb; 132(2):259-264. PubMed ID: 34817082
[TBL] [Abstract][Full Text] [Related]
5. The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP.
Lee SE; Amin N; Mannent LP; Bachert C; Gross G; Cho SH; Praestgaard A; Siddiqui S; Nash S; Kamat S; Khan AH; Jacob Nara JA
Rhinology; 2023 Dec; 61(6):531-540. PubMed ID: 37453138
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
[No Abstract] [Full Text] [Related]
7. Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.
Orlando P; Licci G; Kuitche D; Matucci A; Vultaggio A; Gallo O; Maggiore G
Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1317-1324. PubMed ID: 37910208
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.
Hopkins C; Wagenmann M; Bachert C; Desrosiers M; Han JK; Hellings PW; Lee SE; Msihid J; Radwan A; Rowe P; Amin N; Deniz Y; Ortiz B; Mannent LP; Rout R
Int Forum Allergy Rhinol; 2021 Jul; 11(7):1087-1101. PubMed ID: 33611847
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE.
Mullol J; Lund VJ; Wagenmann M; Han JK; Sousa AN; Smith SG; Mayer B; Chan RH; Fokkens WJ
Rhinology; 2024 Jun; 62(3):320-329. PubMed ID: 38217844
[TBL] [Abstract][Full Text] [Related]
11. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Webster KE; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013513. PubMed ID: 33710614
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.
Lee SE; Hopkins C; Mullol J; Msihid J; Guillemin I; Amin N; Mannent LP; Li Y; Siddiqui S; Chuang CC; Kamat S; Khan AH
Allergy; 2022 Jul; 77(7):2211-2221. PubMed ID: 35034364
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
Fujieda S; Matsune S; Takeno S; Asako M; Takeuchi M; Fujita H; Takahashi Y; Amin N; Deniz Y; Rowe P; Mannent L
Laryngoscope; 2021 Jun; 131(6):E1770-E1777. PubMed ID: 33226139
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP.
Desrosiers M; Mannent LP; Amin N; Canonica GW; Hellings PW; Gevaert P; Mullol J; Lee SE; Fujieda S; Han JK; Hopkins C; Fokkens W; Jankowski R; Cho SH; Mao X; Zhang M; Rice MS; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Bachert C
Rhinology; 2021 Jun; 59(3):301-311. PubMed ID: 33847325
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
Hoy SM
Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
[TBL] [Abstract][Full Text] [Related]
18. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.
Bachert C; Mannent L; Naclerio RM; Mullol J; Ferguson BJ; Gevaert P; Hellings P; Jiao L; Wang L; Evans RR; Pirozzi G; Graham NM; Swanson B; Hamilton JD; Radin A; Gandhi NA; Stahl N; Yancopoulos GD; Sutherland ER
JAMA; 2016 Feb; 315(5):469-79. PubMed ID: 26836729
[TBL] [Abstract][Full Text] [Related]
19. Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review.
Barroso B; Valverde-Monge M; Betancor D; Gómez-López A; Villalobos-Vilda C; González-Cano B; Sastre J
J Investig Allergol Clin Immunol; 2023 Dec; 33(6):419-430. PubMed ID: 37669083
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
Fujieda S; Matsune S; Takeno S; Ohta N; Asako M; Bachert C; Inoue T; Takahashi Y; Fujita H; Deniz Y; Rowe P; Ortiz B; Li Y; Mannent LP
Allergy; 2022 Jan; 77(1):186-196. PubMed ID: 33993501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]